EUVIMEDEUVIMED entdecken
Fallbericht

Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations

Xue Yang, Xintong Li, Jiaqi Yan, Yuanxin Liu, Jie Yin, Weikang Shao, You Lu, Jianxin Xue

Journal of the National Comprehensive Cancer Network · 2025-02 · 23 (2)

DOI: 10.6004/jnccn.2024.7070 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025-02. Verfasst von Xue Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EGFR tyrosine kinase inhibitors (TKIs) have significantly improved clinical outcomes for patients with non–small cell lung cancer (NSCLC) harboring EGFR-activating mutations. However, resistance to TKI therapy often develops due to secondary EGFR mutations or the activation of bypass signalling pathways. Next-generation sequencing (NGS) can efficiently identify actionable genetic alterations throughout treatment. MET amplification is a well-established off-target resistance mechanism. Additionally, rarer mechanisms, such as NTRK1 gene fusions, have been reported. This report highlights a case of a 58-year-old male diagnosed with bone-metastatic NSCLC harboring the EGFR L858R mutation. After receiving dacomitinib and almonertinib sequentially, plasma-based NGS revealed the emergence of EGFR T790M-trans-C797S mutations, prompting a switch to a combination therapy of almonertinib and gefitinib. Upon disease progression, repeat NGS identified EGFR T790M-cis&trans-C797S mutations and a novel POT1 :: NTRK3 fusion in the blood. The fusion retained a complete NTRK kinase domain without frameshift variants, making it a target for treatment. Larotrectinib was incorporated into the dual EGFR-TKI regimen, forming a triplet therapy. Although this resulted in grade 3 dermatitis, the condition resolved after discontinuing gefitinib. At multiorgan progression, matched tissue- and plasma-based NGS identified MET amplification. Subsequently, the patient was started on a triple-inhibition regimen targeting EGFR, NTRK, and MET, which achieved a partial response with favorable tolerability. This is the first reported case of a novel, targetable POT1 :: NTRK3 fusion as a potential off-target mechanism mediating EGFR-TKI resistance, occurring alongside MET amplification in a patient with NSCLC harboring acquired EGFR L858R/T790M/C797S mutations. Concomitant inhibition of EGFR, NTRK, and MET was safe and resulted in a significant response, underscoring the importance of precision medicine guided by matched NGS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedProto-Oncogene Proteins c-metErbB ReceptorsHigh-Throughput Nucleotide SequencingMutationDrug Resistance, Neoplasm

Substanzen

Proto-Oncogene Proteins c-metErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanMET protein, human

Autor:innen und Institutionen

  • Division of Thoracic Tumor Multimodality Treatment, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
  • Genecast Biotechnology Co., Ltd., Wuxi, Jiangsu, China.
  • Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zitieren

APA

Yang, X., Li, X., Yan, J., Liu, Y., Yin, J., Shao, W., Lu, Y., & Xue, J. (2025). Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations. Journal of the National Comprehensive Cancer Network, 23(2). https://doi.org/10.6004/jnccn.2024.7070

Vancouver

Yang X, Li X, Yan J, Liu Y, Yin J, Shao W, et al. Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations. Journal of the National Comprehensive Cancer Network. 2025;23(2). doi:10.6004/jnccn.2024.7070

BibTeX
@article{Yang2025,
  author = {Yang, Xue and Li, Xintong and Yan, Jiaqi and Liu, Yuanxin and Yin, Jie and Shao, Weikang and Lu, You and Xue, Jianxin},
  title = {Response to EGFR/NTRK/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R/T790M/C797S Mutations},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  volume = {23},
  number = {2},
  doi = {10.6004/jnccn.2024.7070}
}
Kostenlos starten →